Infertility Drugs and Devices Market

Infertility Drugs and Devices Market, By Type (Infertility Drugs (Clomiphene citrate, Sex hormones, Gonadotropins, Bromocriptine, Cabergoline, Imipramine, Letrozole, Metformin), Infertility Devices (Equipment, Accessories)), By Gender (Male, Female), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Infertility Drugs and Devices used for treating infertility in male and female. Factors such as endometriosis, ovarian disorders, uterine disorders, tubal disorders, and hormonal disorders are the major cause of female infertility, whereas male infertility is caused by azoospermia, varicocele, ejaculation disorders, and erectile dysfunction. Treatment procedure constitutes of drugs, Assisted Reproductive Technology (ART), surgery, artificial insemination, and in vitro fertilization. Increasing prevalence of erectile dysfunction, increasing research & development, new product approval, and adoption of expansion strategies from major players operating in the market is expected to propel the market growth during the forecast period.

Market Dynamics

The key market players in the market are focused on adopting partnership strategies to expand its product portfolio. For instance, in May 2020, Daré Bioscience, Inc., a developer of women’s health solutions partnered with Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and diagnostic development, under which Health Decisions will exclusively provide CRO services within the U.S. to support R&D of Daré’s pipeline of contraception, fertility, and gynecological disorders products. Moreover, Major players in the market are also focused on launching generic drugs to expand its product portfolio. For instance, in September 2020, Lupin Limited, a multinational pharmaceutical company based in Mumbai, launched Sildenafil tablets, USP of 25 mg, 50 mg, and 100 mg, a generic version of Pfizer Inc.’s Viagra tablets. Moreover, the launch of fertility clinics is another factor in the growth of the market. For instance, in September 2021, Sakra World Hospital began offering infertility treatments, creating personalized treatment regimens for each patient. Such factors would spur market expansion in the near future.

Key features of the study:

• This report provides an in-depth analysis of the global infertility drugs and devices market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global infertility drugs and devices market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include include Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., Pfizer, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc. Mylan Pharmaceuticals Inc., Ferring Pharmaceuticals, Cipla Ltd, Aspargo Laboratories, Inc., Aurobindo Pharma Ltd., Lupin Limited, Novartis International AG, Daré Bioscience, Inc., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals, and Dr. Reddys Laboratories Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global infertility drugs and devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global infertility drugs and devices market.

Detailed Segmentation:

• Global Infertility Drugs and Devices Market, By Type:
• Infertility Drugs
• Clomiphene citrate
• Sex hormones
• Gonadotropins
• Bromocriptine
• Cabergoline
• Imipramine
• Letrozole
• Metformin
• Infertility Devices
• Equipment
• Accessories
• Global Infertility Drugs and Devices Market, By Gender:
• Male
• Female
• Global Infertility Drugs and Devices Market, By Region:
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Apricus Biosciences, Inc.
• Bayer AG
• Cristalia Produtos Quimicos Farmaceuticos Ltda.
• Dong-A Pharmaceutical Co. Ltd.
• Eli Lilly and Company
• Meda Pharmaceuticals, Inc.
• Pfizer, Inc.
• S.K. Chemicals Co. Ltd.
• Vivus, Inc.
• Mylan Pharmaceuticals Inc.
• Ferring Pharmaceuticals
• Cipla Ltd
• Aspargo Laboratories, Inc.
• Aurobindo Pharma Ltd.
• Lupin Limited
• Novartis International AG
• Daré Bioscience, Inc.
• Torrent Pharmaceuticals Ltd.
• Alembic Pharmaceuticals
• Dr. Reddys Laboratories Ltd.